About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 129715, 7 pages
http://dx.doi.org/10.1155/2013/129715
Research Article

HOXA4 Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients

1Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Health Campus 16150 Kubang Kerian, Kelantan, Malaysia
2Haemato-Oncology Unit, Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Health Campus 16150 Kubang Kerian, Kelantan, Malaysia
3Hematology Department, School of Medical Sciences, Universiti Sains Malaysia, Health Campus 16150 Kubang Kerian, Kelantan, Malaysia
4Hospital Pulau Pinang, Malaysia
5Medicine Department & Cell Therapy Centre, UKM Medical Centre, Malaysia

Received 4 October 2012; Accepted 26 November 2012

Academic Editor: Gokce A. Toruner

Copyright © 2013 Marjanu Hikmah Elias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. V. Melo and C. Chuah, “Resistance to imatinib mesylate in chronic myeloid leukaemia,” Cancer Letters, vol. 249, no. 2, pp. 121–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Druker, F. Guilhot, and G. Stephen, “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006.
  3. A. Hochhaus, “Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors,” Annals of Oncology, vol. 17, no. 10, supplement, pp. x274–x279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Mauro, “Defining and managing imatinib resistance,” Hematology, pp. 219–225, 2006. View at Scopus
  5. P. La Rosée and M. W. Deininger, “Resistance to imatinib: mutations and beyond,” Seminars in Hematology, vol. 47, no. 4, pp. 335–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Rochat, “Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents,” Current Cancer Drug Targets, vol. 9, no. 5, pp. 652–674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Strathdee, T. L. Holyoake, A. Sim et al., “Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis,” Clinical Cancer Research, vol. 13, no. 17, pp. 5048–5055, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Jelinek, V. Gharibyan, M. R. H. Estecio et al., “Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia,” PLoS ONE, vol. 6, no. 7, Article ID e22110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. K. Wojdacz, A. Dobrovic, and L. L. Hansen, “Methylation-sensitive high-resolution melting,” Nature Protocols, vol. 3, no. 12, pp. 1903–1908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. K. Wojdacz, T. Borgbo, and L. L. Hansen, “Primer design versus PCR bias in methylation independent PCR amplifications,” Epigenetics, vol. 4, no. 4, pp. 231–234, 2009. View at Scopus
  11. M. Toyota and J. P. J. Issa, “Epigenetic changes in solid and hematopoietic tumors,” Seminars in Oncology, vol. 32, no. 5, pp. 521–531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Dunwell, L. Hesson, T. A. Rauch et al., “A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers,” Molecular Cancer, vol. 9, article 44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. J. Issa, “DNA methylation as a therapeutic target in cancer,” Clinical Cancer Research, vol. 13, no. 6, pp. 1634–1637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Irving, T. Mainou-Fowler, A. Parker, R. E. Ibbotson, D. G. Oscier, and G. Strathdee, “Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia,” Epigenetics, vol. 6, no. 3, pp. 300–306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Zangenberg, L. Grubach, A. Aggerholm et al., “The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML,” European Journal of Haematology, vol. 83, no. 5, pp. 439–448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Strathdee, A. Sim, A. Parker, D. Oscier, and R. Brown, “Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL,” Leukemia, vol. 20, no. 7, pp. 1326–1329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Fournier, C. E. Lebert-Ghali, G. Krosl, and J. J. Bijl, “HOXA4 induces expansion of hematopoietic stem cells in vitro and confers enhancement of pro-B-cells in vivo,” Stem Cells and Development, vol. 21, no. 1, pp. 133–142, 2011.
  18. Z. L. Kelly, A. Michael, S. Butler-Manuel, H. S. Pandha, and R. G. Morgan, “HOX genes in ovarian cancer,” Journal of Ovarian Research, vol. 4, article 16, 2011.
  19. C. Klausen, P. C. K. Leung, and N. Auersperg, “Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of β1 integrin,” Molecular Cancer Research, vol. 7, no. 9, pp. 1425–1437, 2009. View at Publisher · View at Google Scholar · View at Scopus